A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia

Recruiting now · Phase 2

Conditions studied: Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia

In brief

This clinical trial is a multicenter, single-arm, open-label study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of olutasidenib administered orally twice daily under fasting conditions for one cycle of 28 days in at least 3 Japanese patients with relapsed or refractory IDH1 mutation-positive AML.

Key facts

Study ID

NCT07604064

Run by

Kissei Pharmaceutical Co., Ltd.

People needed

3

Starts

2026-06-01

Expected to finish

2030-09-01

Last updated by the study team

2026-05-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Japanese patients who personally provide written informed consent to participate in this clinical trial
• Patients with a confirmed diagnosis of AML based on WHO classification (2022 edition) (except acute promyelocytic leukemia with t (15:17) translocation)
• Patients with relapsed or refractory AML who may or may not have undergone allogeneic hematopoietic stem cell transplantation.
• Patients with IDH1 gene mutation confirmed by central confirmation after relapse or refractoriness

You may not qualify if…

• Patients with IDH2 mutations or patients with a history of IDH2 inhibitor treatment
• Patients who are intolerant to IDH1 inhibitors
• Patients who are deemed inappropriate for the clinical trial by the investigator or sub-investigator

Where it is running

• Research Site — Tokyo and Other Japanese Cities, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.